- Home
- KNOP vs INZY Comparison
KNOP vs INZY Comparison
Compare KNOP & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNOP
- INZY
- Stock Information
- Founded
- KNOP 2013
- INZY 2015
- Country
- KNOP United Kingdom
- INZY United States
- Employees
- KNOP N/A
- INZY N/A
- Industry
- KNOP Marine Transportation
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- KNOP Consumer Discretionary
- INZY Health Care
- Exchange
- KNOP Nasdaq
- INZY Nasdaq
- Market Cap
- KNOP 187.6M
- INZY 188.2M
- IPO Year
- KNOP 2013
- INZY 2020
- Fundamental
- Price
- KNOP $5.62
- INZY $1.36
- Analyst Decision
- KNOP
- INZY Strong Buy
- Analyst Count
- KNOP 0
- INZY 8
- Target Price
- KNOP N/A
- INZY $17.75
- AVG Volume (30 Days)
- KNOP 72.3K
- INZY 1.0M
- Earning Date
- KNOP 02-24-2025
- INZY 03-11-2025
- Dividend Yield
- KNOP 1.87%
- INZY N/A
- EPS Growth
- KNOP N/A
- INZY N/A
- EPS
- KNOP N/A
- INZY N/A
- Revenue
- KNOP $299,790,000.00
- INZY N/A
- Revenue This Year
- KNOP $7.66
- INZY N/A
- Revenue Next Year
- KNOP $1.75
- INZY N/A
- P/E Ratio
- KNOP N/A
- INZY N/A
- Revenue Growth
- KNOP 4.75
- INZY N/A
- 52 Week Low
- KNOP $4.94
- INZY $1.24
- 52 Week High
- KNOP $9.11
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- KNOP 44.69
- INZY 29.28
- Support Level
- KNOP $5.42
- INZY $1.35
- Resistance Level
- KNOP $5.79
- INZY $1.62
- Average True Range (ATR)
- KNOP 0.18
- INZY 0.13
- MACD
- KNOP -0.04
- INZY 0.04
- Stochastic Oscillator
- KNOP 38.24
- INZY 32.89
About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.